William Blair Brokers Boost Earnings Estimates for ResMed

ResMed Inc. (NYSE:RMD) – Research analysts at William Blair lifted their Q3 2025 earnings per share (EPS) estimates for ResMed in a report released on Friday, December 6th. William Blair analyst M. Andrew now forecasts that the medical equipment provider will earn $2.37 per share for the quarter, up from their previous estimate of $2.33. The consensus estimate for ResMed’s current full-year earnings is $9.34 per share. William Blair also issued estimates for ResMed’s Q4 2025 earnings at $2.44 EPS and FY2025 earnings at $9.30 EPS.

RMD has been the topic of several other research reports. KeyCorp upped their price objective on ResMed from $251.00 to $266.00 and gave the company an “overweight” rating in a research note on Friday, October 25th. Baird R W upgraded ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. Wolfe Research restated an “underperform” rating and issued a $180.00 price objective on shares of ResMed in a research note on Wednesday, September 18th. Royal Bank of Canada upped their price objective on ResMed from $224.00 to $232.00 and gave the company a “sector perform” rating in a research note on Friday, October 25th. Finally, Bank of America upped their target price on ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a research report on Thursday, September 26th. One research analyst has rated the stock with a sell rating, five have given a hold rating, six have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has an average rating of “Moderate Buy” and an average price target of $225.70.

ResMed Price Performance

NYSE:RMD opened at $245.22 on Monday. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. The stock’s 50 day moving average price is $242.31 and its two-hundred day moving average price is $226.81. The firm has a market capitalization of $36.00 billion, a price-to-earnings ratio of 32.48, a P/E/G ratio of 1.75 and a beta of 0.68. ResMed has a 12-month low of $162.18 and a 12-month high of $260.49.

ResMed (NYSE:RMD) last released its earnings results on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.03 by $0.17. ResMed had a return on equity of 25.53% and a net margin of 23.15%. The business had revenue of $1.22 billion for the quarter, compared to analyst estimates of $1.19 billion. During the same quarter in the prior year, the company posted $1.64 earnings per share. ResMed’s revenue was up 11.1% on a year-over-year basis.

Institutional Investors Weigh In On ResMed

A number of large investors have recently modified their holdings of RMD. Cetera Advisors LLC bought a new position in shares of ResMed in the 1st quarter valued at $257,000. QRG Capital Management Inc. lifted its stake in shares of ResMed by 4.5% in the 2nd quarter. QRG Capital Management Inc. now owns 1,291 shares of the medical equipment provider’s stock valued at $247,000 after acquiring an additional 56 shares during the last quarter. SG Americas Securities LLC lifted its stake in shares of ResMed by 36.1% in the 2nd quarter. SG Americas Securities LLC now owns 26,717 shares of the medical equipment provider’s stock valued at $5,114,000 after acquiring an additional 7,092 shares during the last quarter. Czech National Bank lifted its stake in shares of ResMed by 8.2% in the 2nd quarter. Czech National Bank now owns 27,995 shares of the medical equipment provider’s stock valued at $5,359,000 after acquiring an additional 2,115 shares during the last quarter. Finally, LVW Advisors LLC bought a new position in shares of ResMed in the 2nd quarter valued at $261,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Insider Buying and Selling

In other ResMed news, CFO Brett Sandercock sold 1,000 shares of the firm’s stock in a transaction on Tuesday, October 8th. The stock was sold at an average price of $233.47, for a total value of $233,470.00. Following the sale, the chief financial officer now owns 95,812 shares of the company’s stock, valued at approximately $22,369,227.64. This trade represents a 1.03 % decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, Director Peter C. Farrell sold 2,000 shares of the firm’s stock in a transaction on Wednesday, December 4th. The shares were sold at an average price of $245.65, for a total value of $491,300.00. Following the completion of the sale, the director now directly owns 81,218 shares in the company, valued at approximately $19,951,201.70. This represents a 2.40 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 52,725 shares of company stock valued at $12,516,248 over the last 90 days. 0.71% of the stock is owned by corporate insiders.

ResMed Announces Dividend

The business also recently declared a quarterly dividend, which will be paid on Thursday, December 12th. Investors of record on Thursday, November 7th will be given a dividend of $0.53 per share. This represents a $2.12 dividend on an annualized basis and a yield of 0.86%. The ex-dividend date of this dividend is Thursday, November 7th. ResMed’s dividend payout ratio is currently 28.08%.

ResMed Company Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.